ReviewAnnals of the American Thoracic Society2014
Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections.
Review in Annals of the American Thoracic Society, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
99 citing papers in PubMed, 2 syntheses or guidelines pooled it, 193 citations in OpenAlex.
- Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.The Cochrane database of systematic reviews · 2020Pooled it
- Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.The Cochrane database of systematic reviews · 2017Pooled it
- Population Pharmacokinetic and Exposure-Response Analysis of Vancomycin Nephrotoxicity in Cystic Fibrosis Patients.Pediatric pulmonology · 2026Article
- Glycoside hydrolases enhance antibiotic activity againstMicrobiology spectrum · 2026Article
- Bacteriophage Therapy: Overcoming Antimicrobial Resistance Through Advanced Delivery Methods.Molecules (Basel, Switzerland) · 2026Review
- Molecular epidemiology ofFrontiers in cellular and infection microbiology · 2026Article
- Protective effects of Staphylococcal Enterotoxin B (SEB) toxoid on lung and liver tissue integrity in rats during systemic infection.Iranian journal of microbiology · 2025Article
- Modeling Cystic Fibrosis Chronic Infection Using Engineered Mucus-like Hydrogels.ACS biomaterials science & engineering · 2024Article
- Practical Guidance for Clinical Microbiology Laboratories: Updated guidance for processing respiratory tract samples from people with cystic fibrosis.Clinical microbiology reviews · 2024Review
- Effect of L-arginine on cystic fibrosisAntimicrobial agents and chemotherapy · 2024Article
- Does "all disease begin in the gut"? The gut-organ cross talk in the microbiome.Applied microbiology and biotechnology · 2024Review
- Cell envelope structural and functional contributions to antibiotic resistance inJournal of bacteriology · 2024Article
- Insights into the Adolescent Cystic Fibrosis Airway Microbiome Using Shotgun Metagenomics.International journal of molecular sciences · 2024Article
- Population pharmacokinetics and target attainment analysis of vancomycin after intermittent dosing in adults with cystic fibrosis.Antimicrobial agents and chemotherapy · 2024Article
- Bibliometric analysis of intestinal microbiota and lung diseases.Frontiers in cellular and infection microbiology · 2024Article
- Anti-Biofilm Activity of Carnosic Acid fromPlants (Basel, Switzerland) · 2023Article
- Upper airway microbiota development in infants with cystic fibrosis diagnosed by newborn screen.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2023Article
- Lytic Bacteriophage Is a Promising Adjunct to Common Antibiotics across Cystic Fibrosis Clinical Strains and Culture Models ofAntibiotics (Basel, Switzerland) · 2023Article
- Antibiotic Resistance in Patients with Cystic Fibrosis: Past, Present, and Future.Antibiotics (Basel, Switzerland) · 2023Review
- Phage-antibiotic synergy reduces Burkholderia cenocepacia population.BMC microbiology · 2023Article
39 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 9 institutions in 6 countries.
Funding
Abstract
Despite significant advances in treatment strategies targeting the underlying defect in cystic fibrosis (CF), airway infection remains an important cause of lung disease. In this two-part series, we review recent evidence related to the complexity of CF airway infection, explore data suggesting the relevance of individual microbial species, and discuss current and future treatment options. In Part I, the evidence with respect to the spectrum of bacteria present in the CF airway, known as the lung microbiome is discussed. Subsequently, the current approach to treat methicillin-resistant Staphylococcus aureus, gram-negative bacteria, as well as multiple coinfections is reviewed. Newer molecular techniques have demonstrated that the airway microbiome consists of a large number of microbes, and the balance between microbes, rather than the mere presence of a single species, may be relevant for disease pathophysiology. A better understanding of this complex environment could help define optimal treatment regimens that target pathogens without affecting others. Although relevance of these organisms is unclear, the pathologic consequences of methicillin-resistant S. aureus infection in patients with CF have been recently determined. New strategies for eradication and treatment of both acute and chronic infections are discussed. Pseudomonas aeruginosa plays a prominent role in CF lung disease, but many other nonfermenting gram-negative bacteria are also found in the CF airway. Many new inhaled antibiotics specifically targeting P. aeruginosa have become available with the hope that they will improve the quality of life for patients. Part I concludes with a discussion of how best to treat patients with multiple coinfections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.